For instance, breast cancers with human epidermal growth factor receptor 2 (HER2) expression have a poorer prognosis, while for colorectal cancer (CRC), tumours with high levels of microsatellite instability (MSI) have a better prognosis [7]. This evidence concerns the gene ERBB2 and colorectal carcinoma.